A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Conditions: Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma Interventions: Drug: CTX-8371 Sponsors: Compass Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Lung Cancer | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Research | Skin Cancer | Squamous Cell Carcinoma